Dr Nima Sharifi speaks to ecancer about HSD3B1 and overall survival in high-risk non-metastatic and metastatic prostate cancer starting androgen deprivation therapy in the enzalutamide and abiraterone acetate plus prednisolone STAMPEDE phase 3 trial.

A study explores the genetic factors influencing castration-resistant prostate cancer and mortality.

It compares standard androgen deprivation therapy with a combination of enzalutamide and abiraterone.

Findings reveal that men with a hyperactive enzyme related to androgen production experience quicker resistance and lower survival rates.

The research highlights the importance of the HST3B1 gene in treatment outcomes and suggests future strategies may target this enzyme to improve resistance management.